The Mayo Clinic in Rochester, MI completed a Phase 1 trial to evaluate treatment of ten patients with asymptomatic ovarian cancer with cancer antigen 125 (CA-125) elevation [113]. The gene discussed is MUC16; the disease is ovarian cancer.